Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06263010 · ClinicalTrials.gov registry record · Phase 1
Allopregnanolone as a Regenerative Treatment for Parkinson's Disease
A Phase 1 study, sponsored by Roberta Brinton.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT06263010 is a Phase 1 study that has completed, run by Roberta Brinton. The registered enrollment target is 10 participants.
The verdict
NCT06263010, a Phase 1 study, has completed, sponsored by Roberta Brinton.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The goal of this open-label, pilot clinical trial is to test allopregnanolone as a regenerative treatment in patients with Parkinson's disease (PD). The main questions this study aims to answer are: 1. Is a large-scale clinical trial testing how well it works in patients with PD feasible? 2. Is allopregnanolone safe and well-tolerated in patients with PD. 3. Can we see any signals of changes in imaging and clinical scales? Participants will receive a weekly infusion in their vein of allopregnanolone for a total of 12 weeks. There is no placebo so everyone receives allopregnanolone and "Open-label" means the study is not blinded so both the participant and investigators know the assigned treatment.
Interventions
- DRUG Allopregnanolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-01-12 |
| Est. Completion | 2025-07-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06263010
The ClinicalTrials.gov registry entry for NCT06263010 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roberta Brinton, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Allopregnanolone is the first listed.
NCT06263010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06263010 about?
NCT06263010 is a clinical study titled "Allopregnanolone as a Regenerative Treatment for Parkinson's Disease". The goal of this open-label, pilot clinical trial is to test allopregnanolone as a regenerative treatment in patients with Parkinson's disease (PD). The main questions this study aims to answer are: 1. Is a large-scale clinical trial testing how well it works in patients with PD feasible? 2. Is all...
What is the current status of trial NCT06263010?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-01-12. Estimated completion is 2025-07-15.
What interventions are being tested in trial NCT06263010?
The interventions under investigation include: Allopregnanolone (DRUG).
Who is sponsoring clinical trial NCT06263010?
This trial is sponsored by Roberta Brinton, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.